Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

Korro Bio (NASDAQ:KRRO) said on Friday that it received U.S. FDA's orphan drug designation for investigational medicine KRRO-110 to treat alpha-1 antitrypsin deficiency. Stock is up about 10% ...

Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ...

For example, biotech and mining... CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Korro Bio (KRRO – Research Report), with a price ...

RBC Capital lowered the firm’s price target on Korro Bio (KRRO) to $95 from $105 and keeps an Outperform rating on the shares. The firm notes ...

Korro Bio completed dosing for its KRRO-110 study in AATD, expects interim results in 2025, and has strong financial resources. Korro Bio, Inc. has completed dosing for the first two cohorts in ...

Read Our Latest Stock Report on KRRO Korro Bio Trading Up 1.1 % KRRO stock opened at $24.03 on Monday. The firm has a 50-day moving average of $29.60 and a two-hundred day moving average of $41.23 ...

So, the natural question for Korro Bio (NASDAQ:KRRO) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative ...

Korro Bio, Inc. (NASDAQ:KRRO) announced today that Vineet Agarwal has resumed his role as Chief Financial Officer after returning from a medical leave that began on February 11, 2025. The company’s ...

Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing therapies, has been making significant strides in the development of treatments for rare genetic disorders, ...